Pfizer Q2 2026 tops expectations on non-COVID strength, lifts guidance

What happened

Pfizer reported Q2 2026 revenue of $15 billion and adjusted EPS of $0.77, both above internal targets, as revenue excluding COVID products grew 5% operationally. Management raised full-year revenue guidance by $500 million at the midpoint, with stronger ex-COVID sales offsetting a cut in expected COVID revenue to roughly $4 billion. The quarter’s net income was pressured by restructuring and amortization charges, but operating income held at $4.7 billion. The results confirm the non-COVID transition is gaining traction, yet growth remains narrowly concentrated in brands like Padcev and Vyndaqel. The next major catalyst is the August 17 FDA decision on broader Padcev use in muscle-invasive bladder cancer.

Implication

Pfizer’s ex-COVID portfolio delivered 5% operational growth, led by Padcev and Lorbrena, but the engine depends on a few key brands that face patent cliffs and pricing headwinds. Cost-saving programs are progressing, yet the $4 billion in restructuring charges and looming 2027 negotiated prices for Ibrance and Xtandi limit margin upside. The $66.3 billion net debt and 4.4x leverage cap valuation, leaving the stock range-bound absent a major catalyst. The August Padcev FDA decision is pivotal: approval could accelerate oncology growth, while a setback would pressure the thesis. With shares near $25.40, risk/reward is balanced; an attractive entry point would require a pullback to $23 or clearer evidence that pricing risks are manageable.

Thesis delta

The Q2 beat and raised guidance modestly strengthen the stabilization narrative but do not alter the rating. Risks from 2027 Medicare pricing and high debt persist, leaving the stock as a WAIT until clearer evidence emerges that growth brands can outpace erosion.